Exhibiting at VIV Asia 2025

Established in 2013, Sichuan Qingmu Pharmaceutical Co., Ltd. is a vertically integrated Chinese pharmaceutical manufacturer and contract development and manufacturing organization (CDMO/CMO), specializing in high-value Active Pharmaceutical Ingredients (APIs), intermediates, and veterinary pharmaceuticals. Based in Meishan, Sichuan Province, the company operates under the brand name Qingmu and serves global pharmaceutical, biotechnology, and veterinary healthcare markets.

Core Business

Qingmu Pharma focuses on the development, scale-up, and GMP-compliant production of APIs and advanced intermediates for both human and animal health. The company is recognized for its strong synthetic chemistry capabilities and regulatory documentation support for global filings.

Product and Service Offerings

Qingmu's diversified portfolio includes:

• Human APIs

  • Bisoprolol Fumarate (Beta-blocker for hypertension)
  • Dabigatran Etexilate Mesylate (Oral anticoagulant)
  • Lenvatinib Mesylate (Tyrosine kinase inhibitor for cancer treatment)

• Veterinary APIs

  • Fluralaner (Systemic acaricide and insecticide for companion animals)
  • Firocoxib (NSAID for dogs and horses)
  • Afoxolaner (Ectoparasiticide for flea and tick control)

• Custom Manufacturing Services

  • Process development and optimization
  • Kilo lab to commercial-scale production
  • Regulatory support including DMF, CEP, and eCTD documentation
  • High-potency and oncology API synthesis

The company supports pharmaceutical clients from R&D through to commercial supply, with batch flexibility and end-to-end traceability.

Specialization and Unique Selling Proposition

Qingmu’s competitive edge lies in its strong process chemistry platform, enabling the development of cost-effective and scalable manufacturing processes for complex molecules. Key USPs include:

• Advanced synthetic route development for patented and off-patent APIs
• High-barrier oncology and cardiovascular APIs with regulatory filings
• EU-GMP and China-GMP compliant facilities
• On-site analytical labs with HPLC, GC, LC-MS/MS, and stability chambers
• Experienced documentation team for global dossier support

The company has also established a strategic R&D alliance with Sichuan University for next-generation molecule development.

Financial Performance

Based on industry estimates and export analytics:

• Estimated Annual Revenue: $20–30 million USD
• Export Contribution: Over 75% of total revenue
• Annual API Production Capacity: Over 150 metric tons
• Year-on-Year Growth: ~18% CAGR (2018–2023)

The revenue is largely driven by long-term supply agreements with global generic drug makers and veterinary pharma companies.

International Shipments & Market Footprint

According to global trade data sources (e.g., ImportYeti, Volza):

• Over 1,800 documented international shipments since 2017
• Top Export Markets: India, Germany, USA, Brazil, Egypt, and South Korea
• Key Exported APIs: Bisoprolol Fumarate, Fluralaner, and Afoxolaner

Qingmu is registered as an approved supplier to several generic drug manufacturers and veterinary formulation plants in the EU and Asia-Pacific.

Target Markets

Qingmu serves:

• Generic and branded pharmaceutical companies
• Veterinary drug manufacturers
• Biotechnology firms
• International API traders and CDMOs
• Research and formulation labs

Their offerings support clients operating in regulated markets (EU, South Korea, Brazil) and semi-regulated zones (MENA, ASEAN, CIS).

Capabilities

• Two GMP-certified production sites with reactor capacities from 50L to 3,000L
• Dedicated facilities for oncology and veterinary API manufacturing
• In-house regulatory affairs team with CEP/DMF filing experience
• R&D center equipped for route scouting, impurity profiling, and scale-up trials
• Strong EHS practices and wastewater treatment in compliance with Chinese EPA norms

Qingmu also offers technology transfer, process validation, and analytical method development as part of its CDMO services.

Certifications and Compliance

• Chinese GMP Certified
• EU-GMP Compliant for select APIs
• ISO 9001:2015 Quality Management System
• DMFs available for multiple APIs (CTD format)
• CEP and/or ANDA support documentation provided upon request
• Regular audits by global pharma clients and third-party quality agencies

All shipments are accompanied by full regulatory documentation, including CoA, MSDS, and traceable batch records.

Customer Testimonials

“Qingmu has been a reliable partner for our fluralaner supply. Their DMF and technical dossier made our filing seamless.”
— Director, Veterinary Pharma Company, Brazil

“We source bisoprolol from Qingmu for EU and LATAM markets. Their batch consistency and regulatory support are first-class.”
— API Procurement Manager, Global Generics Company, Germany

Major Achievements

• DMFs filed in over 15 regulated markets including EU and South Korea
• Exported to more than 30 countries with established distributor networks
• Developed 20+ APIs with high-potency containment capabilities
• Collaborated with Sichuan University for novel oncology compound synthesis
• Regular exhibitor at CPhI Worldwide, API China, and VIV Asia (veterinary segment)

With deep chemistry expertise, regulatory strength, and a growing international footprint, Sichuan Qingmu Pharmaceutical Co., Ltd. stands out as a trusted API manufacturer and CDMO partner for companies seeking innovation, compliance, and scalable supply.